265 related articles for article (PubMed ID: 15312142)
1. TLR9-/- and TLR9+/+ mice display similar immune responses to a DNA vaccine.
Babiuk S; Mookherjee N; Pontarollo R; Griebel P; van Drunen Littel-van den Hurk S; Hecker R; Babiuk L
Immunology; 2004 Sep; 113(1):114-20. PubMed ID: 15312142
[TBL] [Abstract][Full Text] [Related]
2. TLR9 pathway is involved in adjuvant effects of plasmid DNA-based vaccines.
Tudor D; Dubuquoy C; Gaboriau V; Lefèvre F; Charley B; Riffault S
Vaccine; 2005 Jan; 23(10):1258-64. PubMed ID: 15652668
[TBL] [Abstract][Full Text] [Related]
3. Priming of CD8+ T-cell responses after DNA immunization is impaired in TLR9- and MyD88-deficient mice.
Pavlenko M; Leder C; Moreno S; Levitsky V; Pisa P
Vaccine; 2007 Aug; 25(34):6341-7. PubMed ID: 17628235
[TBL] [Abstract][Full Text] [Related]
4. CpG immuno-stimulatory motifs enhance humoral immune responses against hepatitis C virus core protein after DNA-based immunization.
Encke J; zu Putlitz J; Stremmel W; Wands JR
Arch Virol; 2003 Mar; 148(3):435-48. PubMed ID: 12607097
[TBL] [Abstract][Full Text] [Related]
5. TLR9 signals after translocating from the ER to CpG DNA in the lysosome.
Latz E; Schoenemeyer A; Visintin A; Fitzgerald KA; Monks BG; Knetter CF; Lien E; Nilsen NJ; Espevik T; Golenbock DT
Nat Immunol; 2004 Feb; 5(2):190-8. PubMed ID: 14716310
[TBL] [Abstract][Full Text] [Related]
6. Oligodeoxynucleotides containing synthetic immunostimulatory motifs augment potent Th1 immune responses to HBsAg in mice.
Li Y; Kandimalla ER; Yu D; Agrawal S
Int Immunopharmacol; 2005 Jun; 5(6):981-91. PubMed ID: 15829414
[TBL] [Abstract][Full Text] [Related]
7. DNA vaccines in sheep: CTLA-4 mediated targeting and CpG motifs enhance immunogenicity in a DNA prime/protein boost strategy.
Kennedy NJ; Spithill TW; Tennent J; Wood PR; Piedrafita D
Vaccine; 2006 Feb; 24(7):970-9. PubMed ID: 16242220
[TBL] [Abstract][Full Text] [Related]
8. PU.1 and ICSBP control constitutive and IFN-gamma-regulated Tlr9 gene expression in mouse macrophages.
Schroder K; Lichtinger M; Irvine KM; Brion K; Trieu A; Ross IL; Ravasi T; Stacey KJ; Rehli M; Hume DA; Sweet MJ
J Leukoc Biol; 2007 Jun; 81(6):1577-90. PubMed ID: 17360957
[TBL] [Abstract][Full Text] [Related]
9. Direct injection of plasmid DNA into the skin induces dermatitis by activation of monocytes through toll-like receptor 9.
Sawamura D; Abe R; Goto M; Akiyama M; Hemmi H; Akira S; Shimizu H
J Gene Med; 2005 May; 7(5):664-71. PubMed ID: 15655803
[TBL] [Abstract][Full Text] [Related]
10. Non-CpG-containing antisense 2'-methoxyethyl oligonucleotides activate a proinflammatory response independent of Toll-like receptor 9 or myeloid differentiation factor 88.
Senn JJ; Burel S; Henry SP
J Pharmacol Exp Ther; 2005 Sep; 314(3):972-9. PubMed ID: 15919763
[TBL] [Abstract][Full Text] [Related]
11. Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation.
Vollmer J; Weeratna RD; Jurk M; Samulowitz U; McCluskie MJ; Payette P; Davis HL; Schetter C; Krieg AM
Immunology; 2004 Oct; 113(2):212-23. PubMed ID: 15379982
[TBL] [Abstract][Full Text] [Related]
12. Specific siRNA downregulated TLR9 and altered cytokine expression pattern in macrophage after CpG DNA stimulation.
Qiao B; Li B; Yang X; Zhang H; Chu Y; Wang Y; Xiong S
Cell Mol Immunol; 2005 Apr; 2(2):130-5. PubMed ID: 16191419
[TBL] [Abstract][Full Text] [Related]
13. The critical DNA flanking sequences of a CpG oligodeoxynucleotide, but not the 6 base CpG motif, can be replaced with RNA without quantitative or qualitative changes in Toll-like receptor 9-mediated activity.
Sen G; Flora M; Chattopadhyay G; Klinman DM; Lees A; Mond JJ; Snapper CM
Cell Immunol; 2004; 232(1-2):64-74. PubMed ID: 15922717
[TBL] [Abstract][Full Text] [Related]
14. In vitro assay of immunostimulatory activities of plasmid vectors.
Jiang W; Reich CF; Pisetsky DS
Methods Mol Med; 2006; 127():55-70. PubMed ID: 16988446
[TBL] [Abstract][Full Text] [Related]
15. Systemic application of CpG-rich DNA suppresses adaptive T cell immunity via induction of IDO.
Wingender G; Garbi N; Schumak B; Jüngerkes F; Endl E; von Bubnoff D; Steitz J; Striegler J; Moldenhauer G; Tüting T; Heit A; Huster KM; Takikawa O; Akira S; Busch DH; Wagner H; Hämmerling GJ; Knolle PA; Limmer A
Eur J Immunol; 2006 Jan; 36(1):12-20. PubMed ID: 16323249
[TBL] [Abstract][Full Text] [Related]
16. Engineering enhancement of the immune response to HBV DNA vaccine in mice by the use of LIGHT gene adjuvant.
Zhang Y; Jiang W; Fan Y; Wen J; Hao W; Qian M
J Virol Methods; 2008 Nov; 153(2):142-8. PubMed ID: 18722475
[TBL] [Abstract][Full Text] [Related]
17. TLR9 agonists as adjuvants for prophylactic and therapeutic vaccines.
Daubenberger CA
Curr Opin Mol Ther; 2007 Feb; 9(1):45-52. PubMed ID: 17330401
[TBL] [Abstract][Full Text] [Related]
18. TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines.
Ishii KJ; Kawagoe T; Koyama S; Matsui K; Kumar H; Kawai T; Uematsu S; Takeuchi O; Takeshita F; Coban C; Akira S
Nature; 2008 Feb; 451(7179):725-9. PubMed ID: 18256672
[TBL] [Abstract][Full Text] [Related]
19. Toll-like receptors involved in the response to microbial pathogens: development of agonists for toll-like receptor 9.
Schetter C; Vollmer J
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):204-10. PubMed ID: 15603254
[TBL] [Abstract][Full Text] [Related]
20. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
